Novo Nordisk A Slash S

Novo Nordisk A/S, a pharmaceutical preparation manufacturing company headquartered in Denmark, reported a total of approximately 2.69 billion kg CO2e in emissions for 2025. This total comprises approximately 120 million kg CO2e from Scope 1, approximately 63 million kg CO2e from Scope 2 (market-based), and approximately 2.51 billion kg CO2e from Scope 3 emissions. The primary contributors to Scope 3 emissions in 2025 were purchased goods and services, accounting for about 1.38 billion kg CO2e, and capital goods, at approximately 609 million kg CO2e.

In 2024, Novo Nordisk's total emissions were approximately 2.26 billion kg CO2e, with Scope 1 at about 85 million kg CO2e, Scope 2 (market-based) at approximately 16 million kg CO2e, and Scope 3 at approximately 2.16 billion kg CO2e.

The company has established robust climate commitments, including a long-term goal of achieving net-zero emissions across its entire value chain by 2045. For the near term, Novo Nordisk aims to reduce its Scope 3 CO2 emissions by 33% by 2033, using 2024 as a base year. Additionally, they target zero CO2e emissions from operations and transportation by 2030, encompassing both Scope 1 and Scope 2 emissions. As part of their science-based targets, Novo Nordisk commits to 100% absolute reduction of Scope 1 and 2 emissions by 2030 from a 2018 base year. Furthermore, they have set a long-term goal for a 90% absolute reduction in Scope 3 GHG emissions by 2045, also based on a 2024 baseline.